---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-006209"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:41:21.763232+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eton Pharma acquires U.S. rights to HEMANGEOL for $14M upfront

## Summary
- Eton pays $14M upfront plus 8% royalty; $1.5M inventory at close and $0.7M in May 2026.
- HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma; 2025 sales $11.7M.
- Deal financed with cash on hand; expected to be accretive to 2026 earnings.
- Pierre Fabre distributes until April 30; Eton commercializes from May 1 via Eton Cares program.
- Acquisition gives Eton ten commercial rare-disease products, including recent DESMODA approval.

## SEC filing metadata
- accession: 0001437749-26-006209
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926006209/0001437749-26-006209-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926006209/eton20260223c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-006209
- JSON: https://secwatch.observer/filing/0001437749-26-006209.json
- Plain text: https://secwatch.observer/filing/0001437749-26-006209.txt

## Source-grounded claims
- claim_id: 44b95f16f1729a9b412f54108820cead21b40b3c
  claim: Eton Pharmaceuticals, Inc. completed an acquisition involving Pierre Fabre Medicament Sas for $14.0 million upfront and an 8% royalty on net sales for the duration of the product’s patent protected life, plus approximately $1.5 million of inventory at cl (closed 2026-02-27).
  evidence_excerpt: rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre Medicament Sas (“Licensor”). HEMANGEOL® is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000143774926006209/0001437749-26-006209-index.htm
- claim_id: b11c94afee3c9c8df8f0c6a9a1657de62e42f506
  claim: Eton Pharmaceuticals, Inc. entered into Licensing Agreement with Pierre Fabre Medicament Sas valued at $14.0 million upfront (effective 2026-02-27).
  evidence_excerpt: On February 27, 2026, Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) entered into a licensing agreement and acquired the U.S. rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre Medicament Sas (“Licensor”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1710340/000143774926006209/0001437749-26-006209-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.